Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

UFS leads the way with GMO testing
2003-08-25

A formal agreement linking Africa’s first testing facility for genetically modified organisms (GMO) to an international organization was signed at the University of the Free State.

According to the manager of the GMO testing facility, Dr Chris Viljoen of the Department of Plant Sciences, the facility is now part of GeneScan, a world leader in food diagnostic testing, which has its headquarters in Germany with subsidiaries in the Unites States, Brazil and Hong Kong.

The facility at the UFS has been selected by the second largest international food company to do all its South African GMO testing for export products.

The GMO testing facility is the brainchild of Dr Viljoen, who is a specialist in the field of marker biotechnology and its applications in crop science.

He says the need for such a testing facility arose due to the international regulations on GMOs in food, especially Europe and Asia that requires South African exporters to certify whether their products contain any GMO.

“The regulations in Europe and Asia reflect a consumer need for choice in what they eat due to concerns over the safety of GMOs, as well as environmental and ethical issues. GMO testing and labelling allow consumers the right of choice to eat genetically modified foods or not. According to EU regulations, any product with a GMO content of 1% or higher is labelled as containing GMO.”

According to Dr Viljoen only four products in South Africa are currently GMO. They are white and yellow maize that have been made insect resistant, soya bean that is herbicide tolerant and insect resistant cotton. He says that the awareness of GMOs among South Africans is still very limited, especially in poorer communities, but it is likely to increase with the efforts being made in consumer education by government, seed companies and NGOs.

The testing facility has been established to accommodate the local as well as international market. The GMO testing at the UFS facility is performed using real time PCR, the most advanced means of GMO detection currently available, and using GeneScan developed technology that is recognized worldwide.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept